Jonathan R.  Monson net worth and biography

Jonathan Monson Biography and Net Worth

Jonathan Richard Monson holds the position of Chief Accounting Officer, Controller & VP at Boston Scientific Corp. Mr. Monson is also on the board of Boston Scientific International SA and Boston Scientific Ltd.

What is Jonathan R. Monson's net worth?

The estimated net worth of Jonathan R. Monson is at least $3.17 million as of March 31st, 2023. Mr. Monson owns 34,868 shares of Boston Scientific stock worth more than $3,174,731 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Monson may own. Learn More about Jonathan R. Monson's net worth.

How do I contact Jonathan R. Monson?

The corporate mailing address for Mr. Monson and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Jonathan R. Monson's contact information.

Has Jonathan R. Monson been buying or selling shares of Boston Scientific?

Jonathan R. Monson has not been actively trading shares of Boston Scientific in the last ninety days. Most recently, Jonathan Monson sold 5,000 shares of the business's stock in a transaction on Friday, March 31st. The shares were sold at an average price of $50.00, for a transaction totalling $250,000.00. Following the completion of the sale, the chief accounting officer now directly owns 34,868 shares of the company's stock, valued at $1,743,400. Learn More on Jonathan R. Monson's trading history.

Who are Boston Scientific's active insiders?

Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), and David Wichmann (Director). Learn More on Boston Scientific's active insiders.

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, insiders at the medical equipment provider sold shares 21 times. They sold a total of 481,676 shares worth more than $37,970,807.37. The most recent insider tranaction occured on October, 7th when CEO Michael F Mahoney sold 162,777 shares worth more than $13,775,817.51. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 10/7/2024.

Jonathan R. Monson Insider Trading History at Boston Scientific

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2023Sell5,000$50.00$250,000.0034,868View SEC Filing Icon  
3/1/2023Sell5,000$46.66$233,300.0034,868View SEC Filing Icon  
6/16/2021Sell8,833$42.76$377,699.0828,229View SEC Filing Icon  
6/14/2021Sell5,000$42.94$214,700.0042,062View SEC Filing Icon  
See Full Table

Jonathan R. Monson Buying and Selling Activity at Boston Scientific

This chart shows Jonathan Monson's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $91.05
Low: $90.33
High: $91.18

50 Day Range

MA: $85.71
Low: $82.52
High: $90.45

2 Week Range

Now: $91.05
Low: $53.93
High: $91.18

Volume

598,316 shs

Average Volume

6,064,312 shs

Market Capitalization

$134.19 billion

P/E Ratio

75.25

Dividend Yield

N/A

Beta

0.79